<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03656965</url>
  </required_header>
  <id_info>
    <org_study_id>RODKCCC</org_study_id>
    <nct_id>NCT03656965</nct_id>
  </id_info>
  <brief_title>EBV Positive Nasopharyngeal Carcinoma Treated With Concurrent Chemo-radiotherapy With or Without Anti-Viral Drug</brief_title>
  <official_title>Randomized Phase III Study in EBV Positive Locally Advanced Nasopharyngeal Carcinoma Treated With Concurrent Chemo-radiotherapy With or Without Anti-Viral Drug</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kuwait Cancer Control Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kuwait Cancer Control Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      PCR-DNA of EBV test is a good prognostic indicator for survival after treatment (report:
      Prognostic Impact of Plasma, Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma
      Treated using Intensity-Modulated Radiation Therapy.

      The chances of the local recurrence or metastasis are higher in the patients at same stage
      with positive PCR-DNA of EBV in Nasopharyngeal carcinoma after same treatment.(ref.)
      Antiviral drugs have been used to inhibit EBV replication and target viral DNA polymerase are
      Foscarnet and phosphonoacetic acid both interact directly with the pyrophosphate-binding site
      of the enzyme, where Acyclovir as antiviral drug act at two levels: as competitive
      alternative substrates, competing with GTP on the substrate-binding site, and as DNA chain
      terminators, by incorporating into the growing DNA chain and blocking its elongation due to
      their acyclic structure.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Eliminated EBV titre as assessed by quantitative PCR-DNA in patients with NPC.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Drug Use for Unapproved Schedule</condition>
  <arm_group>
    <arm_group_label>Antiviral Drug with Chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antiviral therapy Acyclovir 800 mg per day during the whole course of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive concurrent chemoradiotherapy which consisted of Cisplatin 40 mg/m2 weekly or 100mg/m2 every 3 weeks with IMRT 70Gy/35 fractions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyclovir 800 MG</intervention_name>
    <description>Acyclovir tablets 800 mg per day during the whole course of treatment Or Placebo.</description>
    <arm_group_label>Antiviral Drug with Chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Radiotherapy and chemotherapy</intervention_name>
    <description>Concurrent chemoradiotherapy which consisted of Cisplatin 40 mg/m2 weekly or 100mg/m2 every 3 weeks with IMRT 70Gy/35 fractions.</description>
    <arm_group_label>Antiviral Drug with Chemoradiotherapy</arm_group_label>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed histopathologic diagnosis of nasopharyngeal squamous cell carcinoma, types
             WHO II-III.

          -  Stage II-IVB

          -  Requiring primary concomitant Radiotherapy and Chemotherapy.

          -  No head and neck surgery of the primary tumor or lymph nodes except for incisional or
             excisional biopsies.

          -  Positive PCR-DNA EBV

          -  ≥ 18 years of age

          -  ECOG performance status 0-1

          -  WBC ≥ 4,000/µl, platelets ≥ 100,000/µl; serum creatinine ≤ 1.6 mg/dl or 24 hr.
             calculated creatinine clearance ≥ 60 ml/min (see Section 3.1.6).

          -  Pre-treatment evaluation of tumor extent and tumor measurement.

          -  Nutritional and general physical condition must be considered compatible with the
             proposed radio-therapeutic treatment.

          -  Signed study-specific consent form prior to study entry Assessment.

        Exclusion Criteria:

          -  Prior radiotherapy to the head and neck or any prior chemotherapy ≤ 6 months prior to
             study entry.

          -  Other malignancy except non-melanoma skin cancer or a carcinoma not of head and neck
             origin ≤ 5 years

          -  Evidence of distant metastasis.

          -  on any experimental therapeutic cancer treatment.

          -  major medical or psychiatric illness.

          -  pregnant females.

          -  Age ≤ 18 years old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khaled AlSaleh, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chairman, Radiation Oncology Department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kuwait Cancer Control Center</name>
      <address>
        <city>Kuwait</city>
        <country>Kuwait</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kuwait</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 26, 2018</study_first_submitted>
  <study_first_submitted_qc>August 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2018</study_first_posted>
  <last_update_submitted>August 30, 2018</last_update_submitted>
  <last_update_submitted_qc>August 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kuwait Cancer Control Center</investigator_affiliation>
    <investigator_full_name>Khaled Alsaleh,MD</investigator_full_name>
    <investigator_title>Chairman, Radiation Oncology Department</investigator_title>
  </responsible_party>
  <keyword>EBV</keyword>
  <keyword>Nasopharyngeal Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

